Solid fundamentals with minor concerns to monitor
Gross and operating margins are improving due to a shift to higher-margin products, innovation, and reduced restructuring costs.. Revenue performance was mixed, with growth in Plasma and Hospital segments offset by declines in Blood Center due to a divestiture and customer transition.. The company has $1,224,733 in total debt, with convertible senior notes maturing on March 1, 2026, which will require settlement via cash on hand or revolving credit facility.. Plasma revenue increased 2.8% (constant currency) in Q3 FY26 due to U.S. plasma collections and innovation.